Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Support > Literature Updates

An HIV vaccine blueprint

Science

The impact of therapies against HIV is limited by their cost, clinical infrastructure requirements, and patient adherence. An effective vaccine could be a more cost-effective and practical solution to control the spread of HIV. One approach to develop such a vaccine is to stimulate B cells of the immune system to produce broadly neutralizing antibodies (bnAbs) against the virus. On page 1261 of this issue, Skelly et al. report infecting rhesus macaques with a custom-made virus that was designed to expose a specific bnAb target. Within a year, most of the infected animals developed bnAbs. Eliciting similar bnAbs in humans would probably protect them against HIV infection.

Related products

Catalog No. Product Name Description Target
HW342107 Anti-Human CD134/TNFRSF4/OX40 Antibody (ABS0762) ACT35 antigen, CD134, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, TNFRSF4, TXGP1L, Tumor necrosis factor receptor superfamily member 4

Quick access

Contact Us

  • +86-27-65523339

  • [email protected]

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only